T he 2002 guidelines for the management of osteoporosis published by Osteoporosis Canada 1 identified adequate vitamin D status, in addition to calcium from diet or supplements, as essential for the prevention of osteoporosis. Since then, our knowledge of the role of vitamin D (both D 2 and D 3 ) in fractures, falls and other health outcomes has expanded. Canadian recommendations for vitamin D, which are more than 10 years old, have never been supported by adequately conducted dose-finding studies 2 and were derived primarily from early nutritional science estimates of the minimal intake necessary to prevent extreme deficiency states.
We reviewed advances in knowledge about vitamin D physiology and optimal intake requirements for adults (except in pregnancy and during lactation) to update the 2002 clinical practice guidelines. In reviewing trials of vitamin D, it is important to remember that, unlike the situation for trials of pharmacologic agents, any reported benefits of vitamin D supplementation reflect correction of a deficiency in the population under study.
Methods
We systematically searched the MEDLINE database, for the period 1996 to June 30, 2008 , and the Cochrane Library using the terms "vitamin D," "vitamin D deficiency," "25-hydroxy vitamin D," "meta-analysis" and "systematic review." We identified 168 potentially relevant papers. After removal of duplicates and screening of the abstracts by two reviewers (including A.C.), 16 relevant systematic reviews remained. We included systematic reviews of randomized controlled trials and observational studies that assessed the following outcomes: fractures, falls, death or extraskeletal outcomes. We used the Assessment of Multiple Systematic Reviews instrument 3 to evaluate the methodologic quality of reviews published after the cutoff date for literature reviewed in the 2002 guideline 1 until June 30, 2008 (see Appendices 1 and 2 of the full guideline, 4 available at www.cmaj.ca/cgi/content /full /cmaj.080663/DCI). For levels of evidence and grading of the recommendations, we followed the system used in the 2002 guidelines. 1 A multidisciplinary expert panel, including the authors of this article, reviewed the identified articles. As detailed in Table 1 of the full guideline, 4 we assigned a level of evidence to each summary point (from 1 = highest to 4 = lowest), and a grade to each recommendation, according to a system that incorporated both level of evidence and expert consensus (from A = highest to D = lowest). The Guidelines Committee and the Executive Committee of Osteoporosis Canada's Scientific Advisory Council approved the recommendations.
Assessment of vitamin D Measurement and assay
After synthesis in the skin or ingestion through the diet, vitamin D 3 is stored in the liver, adipose tissue and muscle, where it has a half-life of about 60 days. It is converted into 25-hydroxyvitamin D 3 in the hepatocytes. [5] [6] [7] The serum concentration of 25- 
Key points
• Vitamin D is essential for the prevention of osteoporosis.
• A serum level of 25-hydroxyvitamin D above 75 nmol/L re flects optimal vitamin D intake or synthesis to consis tently improve clinical outcomes such as fracture risk; vitamin D supplementation is needed to achieve this target.
• Recommended intake for low-risk and younger adults should be increased to 10-25 µg (400-1000 IU) daily and for high-risk and older adults, to 20-50 µg (800-2000 IU) daily, with consideration of higher doses (key change from 2002 guideline).
• The half-life of 25-hydroxyvitamin D in the body is 15-20 days. 6 With standard-dose supplementation, serum 25-hydroxy vitamin D plateaus after three to four months. 11 Therefore, to monitor a patient's response, serum 25-hydroxy vitamin D should be measured no sooner than three months after treatment begins. After administration of high-dose oral or parenteral vitamin D replacement (e.g., 500 000 IU), the peak 25-hydroxyvitamin D level may be achieved in one month.
12

Factors associated with vitamin D deficiency
Many factors and conditions are associated with vitamin D deficiency. Some of these are causative (e.g., marked avoidance of ultraviolet radiation or malabsorption) and others are simply associated with decreased exposure to sunlight and poor nutrition (e.g., chronic illness or renal failure).
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Sources of vitamin D Exposure to the sun
The skin synthesizes vitamin D 3 from 7-dehydrocholesterol in response to ultraviolet B radiation in sunlight. 15 This synthetic process depends on many factors, including latitude, altitude, time of year and day, weather, age, skin pigmentation type, clothing, activity and other aspects of the environment. Production of vitamin D in the skin falls to near zero for four to five months of the year in Canada, which raises the risk for vitamin D insufficiency or deficiency.
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Food sources
The influence of the diet on vitamin D status is minimal, given the typical daily intake of 3. 2 Treatment of severe deficiency (rickets or osteomalacia) requires higher doses, e.g., 1250 µg (50 000 IU) daily for two to four weeks, then weekly or biweekly, with monitoring of serum 25-hydroxyvitamin D at one and three months. These dosages are based on an assumption that the patient can absorb an orally administered dose. 
Safety and toxicity of vitamin D supplementation
Excessive use of vitamin D supplements has the potential to cause progressive accumulation and toxic effects, presenting as hypercalcemia and renal damage. Canada's "tolerable upper intake level" (the highest level of daily nutrient intake presenting no risk of adverse effects) is 50 µg (2000 IU) vitamin D for adults.
2 By definition, there is no need to monitor patients' serum calcium or renal function unless doses above the tolerable upper level are administered. However, this level is undoubtedly too conservative and may eventually be revised upward, since toxic effects occur only with prolonged (at least several months) daily intake of more than 1000 µg (40 000 IU). 6, 22 Traditional roles of vitamin D Effect on bone mineral density Low bone mineral density is a risk factor for osteoporotic fracture, and vitamin D deficiency is associated with low bone mineral density. 1 Observational studies have shown an association between higher serum 25-hydroxyvitamin D (range 40-90 nmol/L) and higher bone mineral density. [23] [24] [25] Randomized controlled trials have shown that vitamin D supplements significantly increase bone mineral density.
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Effect on fractures
Observational studies have shown an association between low 25-hydroxyvitamin D and fractures. Clinical trials of vitamin D supplementation have been plagued by methodological issues: lack of determination of optimal dose, poor adherence, 
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Effect on falls Vitamin D may improve muscle strength and lower-extremity function, but the results of studies of fall prevention are inconsistent, because of differences in populations, doses and methods of capturing data on falls. 31, [34] [35] [36] [37] One meta-analysis suggested that vitamin D 3 at a daily dose of 20 µg (800 IU) reduced the risk of falling, particularly in trials that adequately documented the ascertainment of falls.
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Nontraditional roles of vitamin D
Calcitriol is produced locally from circulating 25-hydroxyvitamin D in many tissues (e.g., skin, colon, prostate, breast, pancreas, heart and immune system), a process that is not regu lated by serum calcium, phosphate or parathyroid hormone. 5 Many important physiologic actions of vitamin D outside the musculoskeletal system are now being explored. For example, vitamin D may have important antiproliferative and prodifferentiation properties. 5, 39 Observational studies have shown a relationship between sufficient vitamin D status and lower risk of cancers. [40] [41] [42] Vitamin D may lower blood pressure by downregulating the production of renin. It may also stimulate the production and secretion of insulin and modulate immune function. 5 In epidemiologic studies, low circulating levels of vitamin D were associated with increased risk of multiple sclerosis. 43 Vitamin Ddependent processes affect macrophage lysis of Mycobacterium tuberculosis. 44 Epidemiologic studies have linked vitamin D deficiency in early life with later onset of diabetes mellitus. 45 The nontraditional actions of vitamin D have not been investigated to the same extent as its effects on mineral metabolism. There has been a paucity of intervention studies to test hypothesized benefits, and none of the studies to date used sufficient doses of vitamin D or were adequately powered. Systematic reviews or meta-analyses of the available literature are therefore unlikely to provide answers in this area. A prime example is the recently released, exhaustive report of the Agency for Healthcare Research and Quality, 33 a systematic review of the evidence for vitamin D affecting health outcomes. This review found little or weak evidence supporting the nontraditional actions of vitamin D and could make no recommendations other than that more research is needed.
Summary statements about assessment of vitamin D levels, the safety of supplementation and the roles of vitamin D are presented in Box 1.
Approach to supplementation
Recommendations for vitamin D supplementation are outlined in Box 2. Given the limitations in our knowledge of optimal intake levels, evidence of the safety and potential benefits of vitamin D supplementation support recommendations aiming for serum 25-hydroxyvitamin D levels above 75 nmol/L. For most Canadian adults, exposure to sunlight and dietary intake are insufficient to maintain this level through- *Levels of evidence are explained in detail in the full guideline. 4 In brief, levels of evidence range from very high quality (level 1+, systematic overview or meta-analysis of randomized controlled trials) to very low quality (level 6, case series without controls).
Review out the year, and vitamin D supplementation is therefore indicated. [17] [18] [19] The clinical approach can take into account three "settings," which are based on suspicion for vitamin D insufficiency and its complications. The three settings are low risk for vitamin D deficiency, moderate risk for deficiency and receipt of pharmacologic therapy for osteoporosis.
Vitamin D 3 is the preferred supplementary form for humans, with vitamin D 2 being available for large-dose preparations. Calcitriol and its analogues are prescription products with narrow margins of safety and are not advised for the prevention or treatment of osteoporosis. For most adults, a vitamin D 3 supplement at an initial daily dose of at least 20 µg (800 IU) is appropriate. This dose is unlikely to raise the average serum 25-hydroxyvitamin D level by more than 20 nmol/L. 11, 21 To achieve desirable vitamin D status (> 75 nmol/L), many individuals will require higher doses.
Because vitamin D is stored in body tissues, a larger, less frequent dose may be preferred by some patients. A weekly dose of 250 µg (10 000 IU) vitamin D 3 is available by prescription in some provinces. Some practitioners prescribe vita min D 2 at a dose of 1250 µg (50 000 IU) monthly.
Knowledge gaps
There is need for research to better define the minimum required dose and optimal daily dose for musculoskeletal and other health benefits, as well as the tolerable upper intake level for vitamin D. There is also a need for randomized controlled trials to clarify the benefits and risks (if any) of vitamin D supplementation at that optimal dose. The purported benefits of vitamin D beyond musculoskeletal disorders should be confirmed in clinical trials.
This article has been peer reviewed. 9. Exposure to natural sunlight , when used in moderation (avoiding sunburn) and individualized to the person's skin type, can contribute to summertime vitamin D sufficiency (level 2 evidence, grade B recommendation).
10. Research is needed to better define the minimum required daily dose and the optimal dose for musculoskeletal and other health benefits, and to better establish the tolerable upper level for vitamin D supplementation (grade D recommendation).
*Levels of evidence and grades of recommendations are explained in detail in the full guideline. 4 In brief, grades of recommendations range from A (having level 1 or 1+ evidence plus consensus) to D (having level 4, 5 or 6 evidence and supported by consensus).
